1. Signaling Pathways
  2. Cytoskeleton
  3. Integrin

Integrin

Integrins, a family of heterodimeric adhesion receptors for diverse extracellular matrices, have consistently been implicated as crucial drivers of ovarian cancer development and progression. A number of the RGD-based members of the integrin family, including α5β1, and αvβ3 or αvβ5 integrins, are markedly elevated in aggressive ovarian tumors. These adhesion receptors appear to promote cell adhesion, survival, motility and invasion during ovarian tumor growth or metastatic progression. Importantly, the functions of these integrins are strongly dependent on the activation of focal adhesion kinase (FAK) and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways.

Integrins are transmembrane proteins and are major receptors for cell-extracellular matrix (ECM) and cell-cell adhesion. Modulation of these molecules, particularly αv integrin family, has exhibited profound effects on fibrosis in multiple organ and disease state. Based on the several studies, the integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been known to modulate the fibrotic process via activation of latent transforming growth factor (TGF)-β in pre-clinical models of fibrosis.

Each integrin is typically formed by the non-covalent pairing of one α subunit, of which, 18 types are known to exist, and one β subunit, of which 8 types are known to exist. Together, 24 distinct heterodimers have been identified to date. The αv subunit can form heterodimers with the β1, β3, β5, β6 or β8 subunits and β1 can associate with many different α subunits from α1 to α11, and αv, indicating that not all theoretically possible α and subunit pairs form. Interestingly, the activation of TGF-β appears to be a common function of multiple αv integrins.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10315
    Elarofiban
    Antagonist
    Elarofiban (RWJ-53308) is a nonpeptide, orally active antagonist for fibrinogen receptor αIIbβ3 (GPIIb/IIIa), with an IC50 of 0.15 nM. Elarofiban has the potential for platelet mediated thrombotic disorders research.
    Elarofiban
  • HY-P10783
    BGC0222
    Modulator
    BGC0222 is a novel prodrug of Irinotecan (HY-16562). BGC0222, as a PEG-cRGD-conjugated Irinotecan (HY-16562) derivative, could slowly and steadily release Irinotecan (HY-16562). BGC0222 binds to αVβ3 with IC50 values of 4.25 μM (αVβ3) and 58.7 μM (αVβ5). BGC0222 possesses the property of inducing neovascularization. BGC0222 exhibits good antiproliferation activity in many tumors.
    BGC0222
  • HY-122192
    ICAM-1988
    Antagonist
    ICAM-1988 is a small molecule lymphocyte function-associated antigen-1 (LFA-1) antagonist that disrupts the LFA-1/ICAM-1 interaction and has anti-inflammatory activity.
    ICAM-1988
  • HY-161095
    iRGD-CPT
    iRGD-CPT is a conjugate of iRGD and camptothecin that is covalently coupled through a heterobifunctional linker. iRGD-CPT has anticancer activity in vitroandin vivo. iRGD-CPT can be used for the study of colon cancer.
    iRGD-CPT
  • HY-136699
    Excisanin A
    Inhibitor
    Excisanin A is a potent anticancer agent. Excisanin A inhibits cell proliferation, migration, adhesion and invasion. Excisanin A decreases the expression of MMP-2, MMP-9, p-FAK, p-Src, integrin β1 protein. Excisanin A has the potential for the research of breast cancer.
    Excisanin A
  • HY-P990871
    Anti-CD11a/LFA-1α Antibody (R7-1)
    Anti-CD11a/LFA-1α Antibody (R7-1) is a kind of mouse IgG1 chimeric antibody, targeting to human CD11a/LFA-1α. The recommend isotype control of Anti-CD11a/LFA-1α Antibody (R7-1): Mouse IgG1 kappa, Isotype Control (HY-P99977).
    Anti-CD11a/LFA-1α Antibody (R7-1)
  • HY-125123
    Euchrestaflavanone A
    Euchrestaflavanone A is a flavonoid found in the root bark of Cudrania tricuspidate. Euchrestaflavanone A inhibits platelet aggregation and has some antiplatelet and antithrombotic properties, making it a potential compound for thromboprophylaxis.
    Euchrestaflavanone A
  • HY-P6009
    Cys-αvβ6-BP
    Cys-αvβ6-BP is a cysteine-terminated αvβ6 binding peptide.
    Cys-αvβ6-BP
  • HY-161730
    αvβ1 integrin-IN-3
    Inhibitor
    αvβ1 integrin-IN-3 is a selective αvβ1 integrin inhibitor. αvβ1 integrin-IN-3 has an antifibrotic effect.
    αvβ1 integrin-IN-3
  • HY-P10677
    HB-3-20
    Degrader
    HB-3-20 leads to degradation of the cell surface integrin αVβ5. Transglutaminase 2 (TG2) has specificity for HB-3-20 (kcat/KM=0.16 μM-1min-1).
    HB-3-20
  • HY-10304A
    Orbofiban acetate
    98.13%
    Orbofiban acetate is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation.
    Orbofiban acetate
  • HY-P2633A
    Dentonin TFA
    Dentonin TFA (AC-100 TFA) is a synthetic fragment derived from MEPE. Dentonin TFA enhances osteogenesis by promoting osteoprogenitor adhesion and facilitates immature adherent cells survival. Dentonin TFA has no significant effect to mature osteoblasts. Dentonin TFA can be used for the research of phosphate homeostasis and bone metabolism.
    Dentonin TFA
  • HY-10314A
    Lotrafiban hydrochloride
    Lotrafiban hydrochloride is an orally-active platelet GPIIb/IIIa blocker for research of coronary and cerebrovascular disease.
    Lotrafiban hydrochloride
  • HY-153481A
    ATL 1102 sodium
    Inhibitor
    ATL 1102 sodium is a novel second-generation antisense oligonucleotide to CD49d mRNA
    ATL 1102 sodium
  • HY-172465
    DSPE-PEG5000-cRGD
    DSPE-PEG5000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG5000-cRGD can be used for drug delivery.
    DSPE-PEG5000-cRGD
  • HY-10307
    Roxifiban
    Inhibitor
    Roxifiban is a platelet glycoprotein (GP) IIb/IIIa receptor inhibitor that can be used in the study of angina.
    Roxifiban
  • HY-150124A
    K34c hydrochloride
    Antagonist
    K34c hydrochloride is a potent and selective α5β1 integrin antagonist. By inhibiting α5β1 integrin, K34c hydrochloride reduces chemotherapy-induced premature senescence and promotes apoptosis. K34c hydrochloride can be used in glioblastoma research.
    K34c hydrochloride
  • HY-N15519
    Crocatin B
    Inhibitor
    Crocatin B is found in P. crocatum Ruiz & Pav. Crocatin B exerts anti-inflammatory activity by inhibiting the expression of TNF-α and ICAM-1. Crocatin B has anti-tumor activity.
    Crocatin B
  • HY-118410
    L-738167
    L-738167 is an orally active fibrogen receptor antagonist that prevents the binding of fibrinogen to GP IIb/IIIa. L-738167 can be utilized in thrombus research.
    L-738167
  • HY-P0322A
    GRGDSPK TFA
    Inhibitor
    GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption.
    GRGDSPK TFA
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.